Lilly ha programado sus resultados del tercer trimestre de 2026 para el 29 de octubre. La acción está a 1117,50 EUR antes del mes.

Corea Lilly lanza la campaña del Árbol Azul para el Día Mundial de la Diabetes Los empleados escriben mensajes de apoyo mientras la exhibición del árbol azul destaca la concientización sobre la diabetes el 14 de noviembre

Fidelity Capital Markets is the proposed sale's broker, with an approximate sale date of October 15, 2026. Treasurer Diane M. Stenson signed the notice.

Eli Lilly announces Q3FY26 results on Oct 29. Conference call scheduled for 10:00 am ET. Live webcast available via investor site.

Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company

In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome...

Prelude Therapeutics , a Wilmington, Delaware-based precision oncology company, announced on October 13, 2026 a clinical trial collaboration and supply…

Eli Lilly recently reported fresh clinical and regulatory progress across obesity, diabetes and oncology, including new TOGETHER-PsO biomarker data, global Foundayo rollout plans and an additional FDA indication for Jaypirca in previously untreated CLL/SLL without 17p deletion. The combination of weight-loss franchises like Foundayo and Zepbound, together with oncology assets such as Jaypirca, reinforces Eli Lilly’s effort to spread future revenue across multiple high value therapeutic areas...